心不全の管理：その製品、システム及びビジネスチャンス

当商品の販売は、2011年07月19日を持ちまして終了しました。

原文目次

This report will be a thorough assessment of the current and emerging clinical practice, products and systems for the prevention, screening, diagnosis and management of heart failure. The Report will detail the incidence and prevalence of heart failure, projecting the trend as a result of demographics, intervention or other changes to the population of patients. The Report will detail the current approaches applied by physicians (primary care & cardiologists) and healthcare systems to heart failure. The report will accordingly address clinician and system approaches, detailing the practices, products, and services in use and under development. Products addressed will include monitoring, medicines/drugs and devices. The Report will provide a detailed review of heart failure programs in place through disease management companies, and hospital, home care and outpatient programs. The Report will detail the status of research at a representative number of hospitals toward improving heart failure programs. The report will detail the current and projected market for products in heart failure management encompassing diagnostics, monitoring products, drugs/medicines and devices, with breakdown at these major category levels.

Table of Contents

Executive Summary

Section 1: Introduction

• 1.1 Scope of report
• 1.2 Heart Failure Background
• 1.3 Clinical Background
  • 1.3.1 Description of Symptoms
  • 1.3.2 Treatment Guidelines Under Review
    • 1.3.2.1 New AHA/HFSA Guidelines Previewed at 2002 HFSA Scientific Meeting
    • 1.3.2.2 Heart Failure Specialist, Cardiologist, Primary Care--Impact of Specialist Care on Patient Performance Measures
  • 1.3.3 Statistics
    • 1.3.3.1 Incidence, prevalence
    • 1.3.3.2 Hospital discharges
    • 1.3.3.3 Hospital readmissions
  • 1.3.4 Heart Failure Programs
    • 1.3.4.1 CV Disease Management Companies
    • 1.3.4.2 Hospital Programs
    • 1.3.4.3 Home Care Programs
    • 1.3.4.4 Outpatient Center Programs
      • 1.3.4.4.1 Role of Primary Care, Family Practitioner
      • 1.3.4.4.2 Role of Cardiologist
      • 1.3.4.4.3 PharmD involvement
      • 1.3.4.4.4 Role of Other Physician specialty(ies)
      • 1.3.4.4.5 Role of CV disease management companies

Section 2: Heart Failure-Non-Clinical Issues

• 2.1 Costs and cost-related issues:
  • 2.1.1 Hospitalizations
    • 2.1.1.1 Lost revenues in hospitals due to implementation of a heart failure program which reduced readmissions
    • 2.1.1.2 Net income loss in hospitals due to emergent readmissions of heart failure patients under DRG 127
    • 2.1.1.3 Increase in hosptial revenues from ancillary procedures
    • 2.1.1.4 Effects of nationwide nursing shortage.
    • 2.1.1.5 Efforts underway to manage costs
    • 2.1.1.6 Role of advanced home monitoring in reduction of CHF-related admissions
    • 2.1.1.7 Efforts underway to improve care
    • 2.1.1.8 HFSA’s efforts
    • 2.1.1.9 Achieving cardiac excellence project
    • 2.1.1.10 Communication and friction between the heart failure community and the primary care community
  • 2.1.2 Chronic care
  • 2.1.3 Reimbursement

Section 3: Methods in Managing Heart Failure

• 3.1 Products Currently in use
  • 3.1.1 Monitoring products
    • 3.1.1.1 CO2 rebreathing
    • 3.1.1.2 Heart catheterization
    • 3.1.1.3 Noninvasive hemodynamic monitoring
    • 3.1.1.4 Networked electronic questionnaires
    • 3.1.1.5 Call-in voice mail
    • 3.1.1.6 Weight scales
  • 3.1.2 Medical treatments
    • 3.1.2.1 Diuretics
    • 3.1.2.2 Inotropes
    • 3.1.2.3 Vasodilators
  • 3.1.3 Medical devices treatments
    • 3.1.3.1 Implantable Cardioverter Defibrillators (ICDs)
    • 3.1.3.2 Resynchronization Therapy
• 3.2 New Technologies in the Management and Treatment of Heart Failure

Section 4: Hemodynamic assessments in the Diagnostics, Management, Prevention and Monitoring of Heart Failure

• 4.1 The Role of Hemodynamics and Vascular Function Assessment in Prevention, Treatment and Management of Heart Failure
• 4.2 Current Products Methods/Products/Usage Trends
  • 4.2.1 CO2 Rebreathing
  • 4.2.2 Heart Catheterization
  • 4.2.3 Newer Hemodynamic Measurement Monitoring Methods/Products
    • 4.2.3.1 Ambulatory Blood Pressure Monitoring
    • 4.2.3.2 Impedance Cardiography
    • 4.2.3.3 Implantable Monitoring
    • 4.2.3.4 Noninvasive Measurements/Monitoring
    • 4.2.3.5 Lower-Extremity Bioimpedance
  • 4.2.4 Markets and Opportunities
  • 4.2.5 Products and Competition
  • 4.2.6 Market Forecast 2001-2006
  • 4.2.7 Company Profiles
    • 4.2.7.1 A&D Medical-LifeSource
    • 4.2.7.2 AtCor Medical
    • 4.2.7.3 CardioDynamics International Corporation
    • 4.2.7.4 CardioMEMS
    • 4.2.7.5 CVP Diagnostics
    • 4.2.7.6 Data Sciences International
    • 4.2.7.7 Hypertension Diagnostics, Inc.
    • 4.2.7.8 IEM Americas
    • 4.2.7.9 Medtronic, Inc.
    • 4.2.7.10 Pulse Metric, Inc.
    • 4.2.7.11 Remon Medical Technologies
    • 4.2.7.12 Rozinn Medical
    • 4.2.7.13 Spacelabs Medical division of Instrumentarium
    • 4.2.7.14 SORBA Medical Systems, Inc.
    • 4.2.7.15 SunTech Medical Instruments
    • 4.2.7.16 VivoMetrics, Inc.
    • 4.2.7.17 VSM MedTech Ltd.
    • 4.2.7.18 Wantagh Incorporated

Section 5 THE ROLES OF CARDIOVASCULAR DISEASE MANAGEMENT COMPANIES IN HEART FAILURE

• 5.1 The Evolution of Disease Management Programs
• 5.2 Current and Future Roles of DM in Heart Failure
  • 5.2.1 Guidelines
  • 5.2.2 Program Goals
  • 5.2.3 Company Involvement in Reduction of CHF-Related Hospital Admissions and Readmissions
  • 5.2.4 Assessment Tools Used in Home Monitoring of CHF Patients
    • 5.2.4.1 Call Centers
    • 5.2.4.2 Interactive Voice Response Systems
    • 5.2.4.3 Telemonitoring Devices
    • 5.2.4.4 Enabling Technologies for Home Monitoring of CHF Patients
  • 5.2.5 Review of Market Opportunities and Competition - Company Profiles
    • 5.2.5.1 Alere Medical
    • 5.2.5.2 American Healthways
    • 5.2.5.3 Cardiocom Multi-Disease Management
    • 5.2.5.4 CorSolutions Medical, Inc.
    • 5.2.5.5 CyberCare, Inc.
    • 5.2.5.6 Disease Management Association of America
    • 5.2.5.7 Disease Management Purchasing Consortium & Advisory Counsel
    • 5.2.5.8 Health Alert, Inc.
    • 5.2.5.9 Health Hero Network, Inc.
    • 5.2.5.10 HomMed, LLC
    • 5.2.5.11 I-trax, Inc.
    • 5.2.5.12 LifeMasters Supported SelfCare, Inc.
    • 5.2.5.13 Landacorp, Inc
    • 5.2.5.14 McKesson Health Solutions, LLC
    • 5.2.5.15 Philips Medical (Agilent /HP)
    • 5.2.5.16 Protocol Driven Healthcare, Inc.
    • 5.2.5.17 Qmed Interactive Heart Management

Section 6: APPENDICES

• 6.1 Company Listing-Cardiovascular Disease Management
• 6.2 Company Listing-Heart Failure Management and Treatment Product Manufacturers

関連商品

メドマーケット・ディリジェンス発行の医療機器関連調査レポート

世界の外科用シーラント・接着剤・創傷閉鎖製品・抗癒着製品市場：2010-2017年

Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2010-2017

価格: ￥317,856 (税抜) より

出版日: 2012年02月

世界の脊椎手術（2011年）：製品、技術、市場および機会（2010〜2020年）

Worldwide Spine Surgery 2011: Products, Technologies, Markets & Opportunities, 2010-2020

価格: ￥229,339 (税抜) より

出版日: 2011年07月

世界のアブレーション技術市場（2009年〜2019年）：製品・技術・市場・企業・機会

Ablation Technologies Worldwide Market, 2009-2019: Products, Technologies, Markets, Companies and Opportunities

価格: ￥229,339 (税抜) より

出版日: 2010年06月

無料メールサービス

各カテゴリの最新刊情報やキャンペーン情報をメールにてご案内するサービスです。